BSX

Business Context and Reporting Period

Company: Boston Scientific Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Business Overview: A global developer, manufacturer, and marketer of medical devices for interventional cardiology, peripheral interventions, vascular surgery, electrophysiology, neurovascular intervention, oncology, endoscopy, urology, gynecology, and neuromodulation. The company focuses on less-invasive medical procedures.

Key Financial Metrics (2005)

Segment Sales (2005): Cardiovascular ($4,907M, 78% of total), Endosurgery ($1,228M, 20%), Neuromodulation ($148M, 2%).
Geographic Sales (2005): U.S. ($3,852M), International ($2,431M, 39% of total).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 12% (11% on a constant currency basis), driven primarily by a full year of TAXUS drug-eluting stent sales and growth in Endosurgery and Neuromodulation.
• Profitability Decline: Net income decreased 41% year-over-year. This decline was primarily due to significant one-time charges totaling $894 million (after-tax) in 2005, compared to $332 million in 2004.
• Major Charges: The 2005 charges included a $598 million litigation settlement with Medinol Ltd., $267 million in purchased research and development (R&D) from acquisitions, and $24 million in asset write-downs/optimization costs.
• Market Share Pressure: The company experienced sequential declines in U.S. drug-eluting stent market share during the first three quarters of 2005 due to pricing pressure and competition, though share stabilized in the fourth quarter.
• Acquisitions: In 2005, the company invested over $500 million in approximately 40 strategic alliances and acquisitions, including Advanced Stent Technologies, CryoVascular, Trivascular, and Rubicon Medical.

Guidance, Outlook, Risks, and Unusual Items

Guidance and Outlook

• Guidant Acquisition: On January 25, 2006, Boston Scientific entered a definitive agreement to acquire Guidant Corporation for $27 billion (cash and stock). The transaction is expected to close in April 2006, subject to regulatory approvals. This will significantly diversify revenue into cardiac rhythm management.
• Abbott Transaction: In conjunction with the Guidant deal, Abbott Laboratories will acquire Guidant's vascular businesses and share its drug-eluting stent technology with Boston Scientific.
• Product Launches: Expected to launch the TAXUS Liberté stent in the U.S. in the second half of 2006 and the TAXUS Express 2 in Japan in the first half of 2007.
• 2006 Tax Rate: Management estimates an effective tax rate of approximately 23% for 2006, excluding certain charges.

Material Risks and Contingencies

• FDA Warning Letter: On January 26, 2006, the FDA issued a corporate warning letter citing serious regulatory problems at three facilities and an inadequate corrective action plan. The FDA stated it would not approve new Class III device applications or grant export certificates until deficiencies are corrected. Management does not anticipate delays to the TAXUS Liberté launch but acknowledges the risk of further regulatory action.
• Intellectual Property Litigation: Significant ongoing patent litigation with Johnson & Johnson, Medtronic, and others regarding stent technologies. Outcomes are unpredictable and could limit sales or reduce margins.
• Competition: Increased competition in the drug-eluting stent market, with new entrants expected in the U.S. by late 2007 and already present in Europe (Medtronic, Guidant/XIENCE).
• Debt and Liquidity: The Guidant acquisition will require approximately $8 billion in new borrowings, potentially leading to credit rating downgrades and increased interest costs.

Investor Verification Checklist

• Guidant Closing Conditions: Verify the status of antitrust clearances (Hart-Scott-Rodino and EU) and shareholder approvals required for the $27 billion Guidant acquisition.
• FDA Remediation: Monitor the company's progress in resolving the January 2006 FDA corporate warning letter to ensure no delays in the U.S. launch of the TAXUS Liberté stent.
• Medinol Settlement Impact: Confirm that the $750 million Medinol settlement has fully resolved historical stent litigation and assess the terms of the new arbitration process for future disputes.
• Drug-Eluting Stent Market Share: Track U.S. market share trends for the TAXUS stent system against competitors (Johnson & Johnson/Cypher) as new competitors enter the market.
• Debt Financing Terms: Review the final terms of the $8 billion financing package for the Guidant acquisition, specifically interest rates and covenants, given the potential for credit rating downgrades.